01—Abstract
Summary
Summary of the 10-Q filed July 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Abbott Laboratories reported a solid increase in net sales for the second quarter and first six months of 2025, driven primarily by strong performance in its Medical Devices and Established Pharmaceutical Products segments.
Total net sales grew by 7.4%a in Q2 and 5.7% year-to-date, with growth largely excluding the impact of foreign exchange. The company's profitability saw an improvement, with gross profit margin increasing to 52.7% for both periods, reflecting successful margin improvement initiatives. While the Diagnostic Products segment experienced a decline, largely due to the continued decrease in COVID-19 testing sales, the growth in other segments, particularly Medical Devices with notable strength in Diabetes Care, Heart Failure, and Structural Heart, signals a healthy underlying business.
Financially, Abbott maintained a strong liquidity position with $7.0 billionb in cash and cash equivalents at the end of the period. The company also continued its commitment to returning value to shareholders through dividend payments and share repurchases, with a significant authorization for future buybacks.
Management highlighted ongoing investments in research and development to fuel future growth and successfully managed operating expenses despite increased spending in sales and marketing. The company is also navigating potential legal and tax matters, including ongoing IRS disputes, but management expressed confidence in their ability to manage these issues without material adverse effects on the company's financial standing.
02—Key points
Key Highlights
- Total net sales increased by 7.4% in Q2 2025 and 5.7% for the first six months of 2025 compared to the prior year, with significant growth excluding foreign exchange impacts.
- Medical Devices segment showed robust growth, up 13.4% in Q2 and 11.7% year-to-date (excluding foreign exchange), driven by strong performance in Diabetes Care, Heart Failure, and Structural Heart.
- Established Pharmaceutical Products segment also saw solid growth, with sales up 6.9% in Q2 and 4.9% year-to-date (excluding foreign exchange), particularly in emerging markets.
- Gross profit margin improved to 52.7% for Q2 and year-to-date 2025, up from 51.1% and 50.8% respectively in the prior year periods.
- Diagnostic Products segment sales declined by 1.0% in Q2 and 4.1% year-to-date, largely due to a significant decrease in COVID-19 testing-related sales.
- The company maintained a strong cash position, with $7.0 billion in cash and cash equivalents, and generated $3.5 billion in net cash from operating activities for the first six months of 2025.
- Abbott continues to return capital to shareholders, with a quarterly dividend of $0.59 per share declared and an authorization for up to $7 billion in share repurchases.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2025, Abbott Laboratories kept $0.16.
- Revenue$11.14B100.0%
- Cost of revenue−$4.85B43.6%
- Gross profit$6.29B56.4%
- Operating costs−$4.24B38.0%
- Operating income$2.05B18.4%
- Interest, other & tax−$273.0M2.5%
- Net income$1.78B16.0%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed July 30, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $11.14B$10.38B | +7.4% |
| Cost of Revenue | $4.85B$4.60B | +5.5% |
| Gross Profit | $6.29B$5.77B | +8.9% |
| R&D Expenses | $725.00M$698.00M | +3.9% |
| SG&A Expenses | $3.09B$2.94B | +5.3% |
| Operating Expenses | $9.09B$8.71B | +4.4% |
| Operating Income | $2.05B$1.67B | +22.9% |
| Net Income | $1.78B$1.30B | +36.6% |
| EPS (Basic) | $1.02$0.74 | +37.8% |
| EPS (Diluted) | $1.01$0.74 | +36.5% |
| Shares Outstanding (Basic) | 1.74B1.74B | 0.0% |
| Shares Outstanding (Diluted) | 1.75B1.75B | 0.0% |
05—Questions
Frequently Asked Questions
What is the primary driver of Abbott's sales growth in the reported period?
Abbott's sales growth is primarily driven by its Medical Devices segment, which experienced strong double-digit growth in areas like Diabetes Care, Heart Failure, and Structural Heart, as well as the Established Pharmaceutical Products segment, particularly in emerging markets.
How is the decline in COVID-19 testing sales impacting the company?
The decrease in COVID-19 testing sales continues to impact the Diagnostic Products segment, contributing to its overall sales decline. However, the growth in other segments is offsetting this impact, with COVID-19 testing sales declining to $55 million in Q2 2025 from $102 million in Q2 2024.
What is Abbott's current financial health and liquidity position?
Abbott maintains a strong financial position with $7.0 billion in cash and cash equivalents and generated $3.5 billion in net cash from operating activities in the first six months of 2025. The company also has a favorable debt rating and a significant authorization for share repurchases.
Are there any significant legal or tax risks facing Abbott?
Abbott is involved in several legal proceedings, including lawsuits related to infant formula and ongoing tax disputes with the IRS concerning income reallocation. While management believes these will not have a material adverse effect, the resolution of certain lawsuits, particularly those related to infant formula, could be material to the company's financial results.
06—Continue